A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

Prior treatment

• Acute onset of AD within 4 weeks before drug administration.
• Any history or symptoms of malignant tumors in any organ within 5 years prior to screening, regardless of whether treatment has been received and whether there are signs of recurrence or metastasis
• Having undergone or planned major surgery within 4 weeks prior to drug administration, or unable to fully recover from surgery prior to drug administration.

Other illness

• The accompany disease have been assessed by the investigators during screening period as unsuitable for participation in this study.
• Have a known or suspected history of immunosuppressive diseases, including a history of invasive infections.
• any medical or psychological condition that puts subjects at risk or may affect the study results assessed by investigators.

• Male or female subjects aged ≥18≤75 years old.
• Atopic dermatitis (AD) diagnosed at least half a year before screening.
• Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline.
• Subjects who are suitable for continue using biological treatment assessed by investigator